Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists

Bibliography

• Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009;14:43-65
   PubMed Web of Science ®Google Scholar
• Janero DR, Lindsley L, Vemuri VK, Makriyannis A. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin Drug Discov 2011;6:995-1025
   PubMed Web of Science ®Google Scholar
• Kunos G, Tam J. The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011;163:1423-31
   PubMed Web of Science ®Google Scholar
• Wu Y-K, Yeh C-F, Ly TW, Hung M-S. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Curr Top Med Chem 2011;11:1421-9
   PubMed Web of Science ®Google Scholar
• Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity 2011;19:1325-34
   PubMed Web of Science ®Google Scholar
• Lopez-Moreno JA, Gonzales-Cuevas G, Moreno G, Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 2008;13:160-87
   PubMed Web of Science ®Google Scholar
• Solinas M, Goldberg SR, Piomelli D. The endocananbinoid system in brain reward processes. Br J Pharmacol 2008;154:369-83
   PubMed Web of Science ®Google Scholar
• Fattore L, Melis M, Fadda P, The endocananbinoid system and nondrug rewarding behaviours. Exp Neurol 2010;224:23-6
   PubMed Web of Science ®Google Scholar
• Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 2011;12:638-51
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; published online 12 December 2010; doi:10.1155/2011/179674
   PubMedGoogle Scholar
• Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther 2010;125:138-68
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can Med Assoc J 2011;183:1359-408
   PubMed Web of Science ®Google Scholar
• Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006;27:92-6
   PubMed Web of Science ®Google Scholar
• Smith NJ, Bennett KA, Milligan G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 2011;331:241-7
   PubMed Web of Science ®Google Scholar
• Atwood BK, Wagner-Miller J, Haskins C, Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol 2012;81:250-63
   PubMed Web of Science ®Google Scholar
• Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 2007;9:365-73
   PubMedGoogle Scholar
• Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signaling: therapeutic implications and opportunities. Biochem Pharmacol 2010;80:1-12
   PubMed Web of Science ®Google Scholar
• 7TM Pharma. Press release. 7TM Pharma successfully conducts Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS. Available from: http://ww.7tm.dk/News.aspx?M=News&PID=5&NewsID=58 [Last accessed 20 January 2012]
   Google Scholar
• Cluny NL, Chambers AP, Vemuri VK, The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97:537-43
   PubMed Web of Science ®Google Scholar
• Tam J, Vemuri VK, Liu J, Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-66
   PubMed Web of Science ®Google Scholar
• Vilardaga JP. Theme and variations on kinetics of GPCR activation/deactivation. J Recept Signal Transduct Res 2010;30:304-12
   PubMed Web of Science ®Google Scholar
• Giraldo J. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 2010;15:411-15
   PubMed Web of Science ®Google Scholar
• Howlett AC, Reggio PH, Childers SR, Endocannaibnoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 2011;163:1329-43
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005;76:1307-24
   PubMed Web of Science ®Google Scholar
• Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 2001;414:135-43
   PubMed Web of Science ®Google Scholar
• Erdozain AM, DIez-Alarcia R, Meana JJ, Callado LF. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from post mortem human brain. Biochem Pharmacol 2011;83:260-8
   PubMed Web of Science ®Google Scholar
• Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009;60:77-84
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010;62:588-631
   PubMed Web of Science ®Google Scholar
• Lopez-Moreno JA, Lopez-Jimenez A, Gorriti MA, Rodriguez de Fonseca F. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010;11:406-28
   PubMed Web of Science ®Google Scholar
• Hill MN, Patel S, Campolongo P, Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010;30:14980-6
   PubMed Web of Science ®Google Scholar
• Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 2008;88:335-69
   Web of Science ®Google Scholar
• Rinaldi-Carmona M, Pialot F, Cogny C, Characterization and distribution of binding sites for [3H]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996;58:1239-47
   PubMed Web of Science ®Google Scholar
• Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2011; published online 29 April 2011; doi:10.1177/1073858410397377
   PubMed Web of Science ®Google Scholar
• Chiu CQ, Puente N, Grandes P, Castillo PE. Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 2010;30:7236-48
   PubMed Web of Science ®Google Scholar
• Przbyla JA, Watts VJ. Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor herterodimers. J Pharmacol Exp Ther 2010;332:710-19
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Cascio MG, Fernandez-Ruiz J, Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002;954:73-81
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002;66:77-84
   PubMed Web of Science ®Google Scholar
• Bortolato M, Frau R, Bini V, Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB1 cannabinoid receptors. J Psychiatr Res 2010;44:944-55
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Goodwin RS, Li CT, Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2011; published online 12 July 2011; doi:10.1308/mp.2011.82
   Web of Science ®Google Scholar
• Zhang PW, Ishiguro H, Ohtsuki T, Human cannabinoid receptor 1:5 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004;9:916-31
   PubMed Web of Science ®Google Scholar
• Chen X, Williamson VS, An SS, Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry 2008;65:816-24
   PubMed Web of Science ®Google Scholar
• Proudnikov D, Kroslak T, Sipe JC, Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J 2010;10:232-42
   PubMed Web of Science ®Google Scholar
• Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonesca F. The endocananbinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010;95:375-82
   PubMed Web of Science ®Google Scholar
• Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5:1-8
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Aguilar MA, Rodriguez-Arias M, Cannabinoid agonist-induced sensitization to morphine place preference in mice. Neuroreport 2004;15:1371-7
   Google Scholar
• Solinas M, Panlilio LV, Tanda G, Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005;30:2046-57
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cuevas G, Aujla H, Martin-Fardon R, Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters subsequent cocaine seeking behavior. Neuropsychopharmacology 2007;32:2260-6
   PubMed Web of Science ®Google Scholar
• Malinen H, Hyytia P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin Exp Res 2008;32:1976-83
   PubMed Web of Science ®Google Scholar
• Manzanedo C, Rodriguez-Arias M, Daza-Losada M, Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behav Brain Funct 2010; published online 22 March 2010; doi:10.1186/1744-9081-6-19
   PubMed Web of Science ®Google Scholar
• Gamaleddin I, Wertheim C, Zhu AZ, Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 2011; published online 26 April 2011; doi:10.1111/j.1369-1600.2011.00314x
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Qian L, Wood JT, Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 2006;83:396-402
   PubMed Web of Science ®Google Scholar
• Droste SM, Saland SK, Schlitter EK, Rodefer JS. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav 2010;95:443-8
   PubMed Web of Science ®Google Scholar
• Wagner JD, Zhang L, Kavanagh K, A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther 2010;335:103-13
   PubMed Web of Science ®Google Scholar
• Fong TM, Guan X-M, Marsh DJ, Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridine-2-yl]oxy}propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007;321:1013-22
   PubMed Web of Science ®Google Scholar
• Solinas M, Panlilo LV, Antoniou K, The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedule of drug self-administration in rats. J Pharmacol Exp Ther 2003;306:93-102
   PubMed Web of Science ®Google Scholar
• Xi ZX, Gilbert JG, Peng XQ, Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci 2006;26:8531-6
   PubMed Web of Science ®Google Scholar
• Azizi P, Haghparast A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats. Behav Brain Res 2009;197:119-24
   PubMed Web of Science ®Google Scholar
• de Bruin NM, Lange JH, Kruse CG, SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res 2011;217:408-15
   PubMed Web of Science ®Google Scholar
• Daza-Losada M, Minarro J, Aguilar MA, Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference. Pharmacol Biochem Behav 2011;100:33-9
   PubMed Web of Science ®Google Scholar
• Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006;66:2109-19
   PubMed Web of Science ®Google Scholar
• Hagmann WK. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm 2008;341:405-11
   PubMed Web of Science ®Google Scholar
• Lange JH, van der Neut MA, den Hartog AP, Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists. Bioorg Med Chem Lett 2010;20:1752-7
   PubMed Web of Science ®Google Scholar
• Lamota L, Bermudez-Silva FJ, Marco EM, Effects of adolescent nicotine and SR 147778 (surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 2008;54:194-205
   PubMed Web of Science ®Google Scholar
• Scheen AJ. CB1 Receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO program with rimonabant. J Neuroendocrinol 2008;20:S139-46
   PubMed Web of Science ®Google Scholar
• Despres JP. Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 2009;15:553-70
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Hollander P, Fujioka K, A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab 2010;12:517-31
   PubMed Web of Science ®Google Scholar
• Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011;36:10-18
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Finer N, Hollander PA, Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity 2011;19:1404-14
   PubMed Web of Science ®Google Scholar
• Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011; published online 24 January 2011; doi:10.1002/14651858.CD005353.pub4
   Web of Science ®Google Scholar
• Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med 2011; published online 12 October 2011; doi:10.231/JIM.0b013e31823581fa
   PubMed Web of Science ®Google Scholar
• Soyka M, Koller G, Schmidt P, Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008;28:317-24
   PubMed Web of Science ®Google Scholar
• Morrison MF, Ceesay P, Gantz I, Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl) 2010;209:245-53
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Tonstad S, Moreno M, A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes 2010;34:919-35
   Web of Science ®Google Scholar
• Proietto J, Rissanen A, Harp JB, A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes 2010;34:1243-54
   Web of Science ®Google Scholar
• Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 2008;7:961-6
   PubMed Web of Science ®Google Scholar
• Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes 2009;33:947-55
   PubMed Web of Science ®Google Scholar
• Martin-Garcia E, Burokas A, Martin M, Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem 2010;112:1338-51
   PubMed Web of Science ®Google Scholar
• Moriera FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009;23:133-44
   PubMed Web of Science ®Google Scholar
• Maccioni P, Colombo G, Carai MA. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. CNS Neurol Disord Drug Targets 2010;9:55-9
   PubMed Web of Science ®Google Scholar
• Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009;205:171-4
   PubMed Web of Science ®Google Scholar
• Valverde O. Participation of the endocannabinoid system in the regulation of emotional-like behavior. Curr Pharm Des 2005;11:3241-9
   Google Scholar
• Hill MN, Gorzalka BB. Impairments in endocananbinoid signaling and depressive illness. JAMA 2009;301:1165-6
   PubMed Web of Science ®Google Scholar
• Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviors and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001;70:123-31
   PubMed Web of Science ®Google Scholar
• Gribel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57:261-7
   PubMed Web of Science ®Google Scholar
• Thiemann G, Watt CA, Ledent C, Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 2009;200:67
   Google Scholar
• Martin-Garcia E, Burokas A, Martin M, Central and peripheral consequences of the chronic blockade of CB1 receptor with rimonabant or taranabant. J Neurochem 2010;112:1138-51
   PubMedGoogle Scholar
• Aso A, Ozaita A, Serra MA, Maldonado R. Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype. Eur Neuropsychopharmacol 2011;21:11-22
   PubMed Web of Science ®Google Scholar
• Receveur J-M, Murray A, Linget J-M, Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain barrier. Bioorg Med Chem Lett 2010;20:453-7
   PubMed Web of Science ®Google Scholar
• Hortala L, Rinaldi-Carmona M, Congy C, Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif. Bioorg Med Chem Lett 2010;20:4573-7
   PubMed Web of Science ®Google Scholar
• Hung M-S, Chang C-P, Li T-C, Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. Chem Med Chem 2010;5:1439-43
   Web of Science ®Google Scholar
• Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2011; published online 8 August 2011; doi:10.1177/0269881111408458
   PubMed Web of Science ®Google Scholar
• Quarta C, Mazza R, Obici S, Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 2011;17:518-26
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-36
   PubMed Web of Science ®Google Scholar
• Gifford AN, Bruneus M, Gatley SJ, Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 1999;288:478-83
   PubMed Web of Science ®Google Scholar
• Addy C, Wright H, Van Laere K, The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78
   PubMed Web of Science ®Google Scholar
• Borisenko SA. Effects of drugs on blood-brain barrier permeability in rats chronically intoxicated by ethanol. Ann Ist Super Sanita 1990;26:39-42
   PubMedGoogle Scholar
• Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol 2004;19:535-64
   PubMed Web of Science ®Google Scholar
• Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 2006;1074:198-224
   PubMed Web of Science ®Google Scholar
• Dietrich JB. Alteration of blood-brain barrier function by methamphetamine and cocaine. Cell Tissue Res 2009;336:385-92
   PubMed Web of Science ®Google Scholar
• Sharma HS, Sjoquist PO, Ali SF. Alterations in blood-brain barrier function and brain pathology by morphine in the rat. Neuroprotective effects of antioxidant H-290/51. Acta Neurochir 2010;106:S61-6
   Google Scholar
• Izzo AA, Mascolo N, Borrelli F, Capasso F. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedberg's Arch Pharmacol 1999;359:65-70
   PubMed Web of Science ®Google Scholar
• Lehmann A, Blackshaw LA, Branden L, Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002;123:1129-34
   PubMed Web of Science ®Google Scholar
• Storr MA, Bashasati M, Hirota C, Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 2010;22:787-97
   PubMedGoogle Scholar
• Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010;126:21-38
   PubMed Web of Science ®Google Scholar
• Chambers AP, Vemuri VK, Peng Y, A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293:R2185-93
   PubMed Web of Science ®Google Scholar
• Fride E, Braun H, Matan H, Inhibition of milk ingestion and growth after administration of a neutral acannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007;62:533-6
   PubMed Web of Science ®Google Scholar
• Salamone JD, McLaughlin PJ, Sink K, Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007;91:383-8
   PubMed Web of Science ®Google Scholar
• Sink KS, McLaughlin PJ, Wood JA, The novel cannabinoid CB1R receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33:946-55
   PubMed Web of Science ®Google Scholar
• Bostrom J, Olsson RI, Tholander J, Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett 2010;20:479-82
   PubMed Web of Science ®Google Scholar
• Lin Y, Shia K-S, Hsiao W-C, Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities. Pharmacol Res 2010;62:337-43
   PubMed Web of Science ®Google Scholar
• Cluny NL, Chambers AP, Vemuri VK, The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97:537-43
   PubMed Web of Science ®Google Scholar
• Lafenetre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 recpetors may modulate fear extinction. Pharmacol Res 2007;56:367-81
   PubMed Web of Science ®Google Scholar
• Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology 2010;215:629-46
   PubMed Web of Science ®Google Scholar
• Riebe CJ, Wotjak CT. Endocannabinoids and stress. Stress 2011;14:384-97
   PubMed Web of Science ®Google Scholar
• Das UN. Obesity: genes, brain, gut, and environment. Nutrition 2010;26:459-73
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Goparaju SK, Wang L, Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5
   PubMed Web of Science ®Google Scholar
• Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol 2011; published online 26 December 2011; doi:10.1111/j.1748-1716.2011.02402.x
   Web of Science ®Google Scholar
• Panagis G, Vlachou S, Nomikos GG. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev 2008;1:350-74
   PubMedGoogle Scholar
• Panlilio LV, Justinova Z, Goldberg SR. Animal models of cannabinoid reward. Br J Pharmacol 2010;160:499-510
   PubMed Web of Science ®Google Scholar
• Stewart A, Wong K, Cachat J, Zebrafish models to study drug abuse-related phenotypes. Rev Neurosci 2011;22:95-105
   PubMed Web of Science ®Google Scholar
• Fernando AB, Robbins TW. Animal models of neuropsychiatric disorders. Annu Rev Clin Psychol 2011;7:39-61
   PubMed Web of Science ®Google Scholar
• Horswill JG, Bali U, Shaaban S, PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007;152:805-14
   PubMed Web of Science ®Google Scholar
• Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 2010;160:454-66
   PubMed Web of Science ®Google Scholar
• Xi Z-X, Peng X-Q, Li X, Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011;14:1160-8
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155-63
   PubMed Web of Science ®Google Scholar
• Cinar R, Szucs M. CB1 receptor-independent actions of SR 141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. J Pharmacol Exp Ther 2009;330:567-74
   PubMed Web of Science ®Google Scholar
• Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943 – 2011). Science 2011;334:466
   PubMed Web of Science ®Google Scholar